Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423);Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2196-2203

  Yoon, Harry H ^a   Bendell, J C ^b   Braiteh, F S ^c   Firdaus, I ^d,k   Philip, P A ^e   Cohn, A L ^f   Lewis, N ^g,l   Anderson, D M ^h   Arrowsmith, E ^b   Schwartz, J D ^i,m   Gao, L ⁱ   Hsu, Y ⁱ   Xu, Y ⁱ   Ferry, D ⁱ   Alberts, S R ^a   Wainberg, Z A ^j  

^a MAYO CLINIC   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Medical Oncology Comprehensive Cancer Centers of Nevada   (United States)

^d Sarah Cannon Research Institute Oncology Hematology Care Inc   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROCKY MOUNTAIN CANCER CENTERS   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h Metro Minnesota Community Clinical Oncology Program   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CHRIST HOSPITAL   (United States)

^l NOVARTIS PHARMA AG   (Switzerland)

^m Rocket Pharmaceuticals Ltd   (United States)

more..

Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal junction; Ramucirumab; Vascular endothelial growth factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CAUCASIAN; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 85030256768     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdz454     Document Type: Erratum

References (18)

1. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
2. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442
3. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499
4. Cunningham D, Tebbutt NC, Davidenko I et al. MetGastric: phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33(suppl): abstr 4000
5. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
6. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
7. O'Brien L, Westwood P, Gao L, Heathman M. Population pharmacokinetic metaanalysis of ramucirumab in cancer patients. J Pharmacokinet Pharmacodyn 2015; 42(1 suppl): abstr M-10
8. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
9. Shen L, Li J, Xu J et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176
10. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976
11. Enzinger PC, McCleary NJ, Zheng H et al. Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA). J Clin Oncol 2016; 34(suppl 4s): abstr 4
12. Enzinger PC, Burtness B, Niedzwiecki D et al. CALGB 80403/ECOG 1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol 2016; 34: 2736-2742
13. Garcia-Carbonero R, Rivera F, Maurel J et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014; 19: 350-351
14. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
15. Tabernero J, Ohtsu A, Muro K et al. Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 2015; 33(suppl 3): abstr 121
16. Feng Y, Roy A, Masson E et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013; 19: 3977-3986
17. Cosson VF, Ng VW, Lehle M, Lum BL. Population pharmacokinetics and exposureresponse analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 2014; 73: 737-747
18. Wang J, Song P, Schrieber S et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 2014; 95: 558-564